Deal Details
Immunovant Completes $200 Million Follow-On Offering
Summary
Immunovant, Inc. (“Immunovant”) (NASDAQ-GS: IMVT) recently completed an underwritten public offering of 6,060,606 shares of its common stock at a public offering price of $33.00 per share, which included the exercise in full by the underwriters of their option to purchase an additional 790,513 shares of common stock. The aggregate gross proceeds to Immunovant from the offering are approximately $200.0 million.
Baird served as co-lead manager on this offering.
About
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. Immunovant, Inc. is headquartered in New York, New York.CONTACT US TO LEARN MORE
- Date
- September 2020
- Company
- Immunovant, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
